<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100512'>Vitamin D deficiency</z:hpo> predisposes individuals to type 1 and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and receptors for its activated form-1alpha,25-dihydroxyvitamin D3-have been identified in both beta cells and immune cells </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0100512'>Vitamin D deficiency</z:hpo> has been shown to impair insulin synthesis and secretion in humans and in animal models of <z:mp ids='MP_0002055'>diabetes</z:mp>, suggesting a role in the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, epidemiological studies suggest a link between <z:hpo ids='HP_0100512'>vitamin D deficiency</z:hpo> in early life and the later <z:hpo ids='HP_0003674'>onset</z:hpo> of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In some populations, type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with certain polymorphisms within the <z:chebi fb="27" ids="27300">vitamin D</z:chebi> receptor gene </plain></SENT>
<SENT sid="4" pm="."><plain>In studies in nonobese diabetic mice, pharmacological doses of <z:chebi fb="0" ids="17823">1alpha,25-dihydroxyvitamin D3</z:chebi>, or its structural analogues, have been shown to delay the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0002055'>diabetes</z:mp>, mainly through immune modulation </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0100512'>Vitamin D deficiency</z:hpo> may, therefore, be involved in the pathogenesis of both forms of <z:mp ids='MP_0002055'>diabetes</z:mp>, and a better understanding of the mechanisms involved could lead to the development of preventive strategies </plain></SENT>
</text></document>